I think it's a bit too early to judge on GT20029s efficacy...
Yes CB-03-01 performed the best for Sebaceous gland growth inhibition according to the table:
View attachment 170679
Although this is a test on the sebaceous gland which they did to test it's efficacy against acne,
I don't think it's safe to assume that this will also be the case for dermal papilla when testing against hair loss..
In another experiment designed for treating hair loss when head to head with 5% minoxidil, 1% and 3%
GT20029 performed just as well at 5% Minoxidil on day 17. Let's also not forget mice are good responders to minoxidil.
"In this experiment, 6 groups were used, namely, a Vehicle group, a DHT (30mg/kg) concentration group, a DHT (30mg/kg) + minoxidil 5% concentration group, a DHT (30mg/kg) + A460.5% concentration group, a DHT (30mg/kg) + A461% concentration group and a DHT (30mg/kg) + A463% concentration group. The results of hair regrowth in the androgen alopecia model in C57 mice are shown in table 9 below: table 9 hair regrowth effect on C57 mouse androgen alopecia model (AVER, n ═ 6) As can be seen from the results, the DHT (30mg/kg) concentration group scored 0.5 for hair development 17 days after the administration, and had almost no hair development, which was significantly lower than that of the Vehicle group, indicating successful molding. The average value of the score of the DHT (30mg/kg) + minoxidil 5% concentration group is 2.33, which is obviously higher than that of the DHT (30mg/kg) model group, and the DHT/minoxidil composition shows good hair growth effect. The DHT (30mg/kg) + A460.5% concentration group scored slightly higher than the building block DHT (dihydrotestosterone) group, but there was no statistical difference. The scores at Day17 for the A461% and 3% concentration dose groups were approximately equivalent to the 5% minoxidil group, and the scores were significantly different from the DHT (dihydrotestosterone) group (p < 0.05; p < 0.01)."
Patent Source: https://patents.google.com/patent/CN113387930A/en?assignee=Suzhou+Kintor+Pharmaceuticals,+Inc.&sort=new
There still could be adjustments needed for the vehicle since the molecule size for GT20029 is quite large.
Finally if you are comparing it to CB-03-01, let's not forget that CB-03-01 massively drops after the 6 month mark (maybe due to the upregulation of receptors when using an an AR antagonists), this might not happen with AR degraders.
View attachment 170681